# A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

> **NCT02079532** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 302 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** rituximab [MabThera]

## Key facts

- **NCT ID:** NCT02079532
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2016-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079532, "A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02079532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*